Evidence-Based Veterinary Medicine Matters: Our Commitment to the Future represents the first time that such a broad and influential group has united in support of a single issue in the veterinary profession.
The publication contains a number of case studies which illustrate the impact that evidence can have – and has had – on animal health and welfare. It also provides a rationale for veterinary professionals to contribute to the evidence base and put evidence into practice, to the benefit of animals, owners and veterinary teams themselves.
The signatories to the commitment are:
Animal and Plant Health Agency
British Cattle Veterinary Association
British Equine Veterinary Association
British Small Animal Veterinary Association
British Veterinary Association
British Veterinary Nursing Association
RCVS Knowledge
Royal College of Veterinary Surgeons (RCVS)
Royal Veterinary College
University of Bristol
University of Cambridge
University of Liverpool
University of Nottingham
University of Surrey
Veterinary Policy Research Foundation
No sign of the BAHVS, I see.
Jacqui Molyneux, Chair of the Board of Trustees of RCVS Knowledge, said: "Evidence-Based Veterinary Medicine Matters is a milestone publication for the professions, representing the first time the majority of the key institutions have aligned under the same EBVM banner.
"A celebration of decades of incredible discoveries, achievements and improvements in animal health, it also serves to remind us that even the earliest forms of veterinary medicine were underpinned by evidence."
UK Chief Vet Christine Middlemiss said: "What’s the evidence? An evidence-based approach is vital in all areas of our profession, whatever is keeping you awake at night. For me, it is the threat of African swine fever and avian flu. The evidence I rely on comes from our specialist surveillance monitoring and testing, veterinary epidemiologists and disease modellers. It enables me to make timely, proportionate risk-based decisions that stand up to scrutiny.
"If you are managing veterinary care in practice, the evidence you rely on to underpin your standards of clinical care comes from multiple sources too. Evidence-based veterinary medicine allows us to refine and tailor strategies to be effective and efficient, making full use of existing and new technologies.
"The profession has taken great strides towards embracing evidence-based veterinary medicine and building on this will strengthen the links between clinical decision-making, policy development and future research."
Chris Gush, Executive Director of RCVS Knowledge, added: "We are impressed by the contributions from our co-signatories, which clearly demonstrate the phenomenal impact on patient outcomes that conducting research and using evidence can have. We are also delighted that Sense about Science, a flagbearer for evidence, transparency and rational thinking, has joined with us to highlight the many benefits EBVM can bring.
"The publication also makes a strong case for much-needed funding for research to grow the evidence base, which would put powerful, robust data into the hands of veterinary professionals as they make critical decisions that can affect patient outcomes.
"It is our hope that the calibre, diversity and sheer number of the organisations putting their name to this commitment will galvanise all vets and their teams to expand their use of evidence in practice."
Rebecca Asher, Deputy Director at Sense about Science, said: "This is a showcase of game changers in veterinary care and we hope it will inspire and motivate everyone in the profession.
"We were delighted that RCVS Knowledge approached us to collaborate with them and other leading institutions in the veterinary research community to affirm their commitment to an evidence-based approach to veterinary medicine.
"Everyone expects treatment for humans to be underpinned by evidence. We now expect the same of the whole veterinary community when it comes to the treatment of animals."
The full commitment and portfolio of case studies can be read in Evidence-Based Veterinary Medicine Matters, available for free online: bit.ly/EBVMMatters.
Sarah is a Professor of Veterinary Surgery at the University of Nottingham’s School of Veterinary Medicine & Science, and leads the Nottingham Equine Colic Project, which works with organisations such as the British Horse Society to raise awareness of the condition.
Sarah's talk, 'Generating an evidence-based educational campaign on colic', will discuss new evidence from the project, and how it led to the REACT colic campaign. She will also be sharing experiences of how the campaign has worked and asking whether we can change people's attitudes and behaviours.
The evening starts at 6.15pm with food and refreshments with Sarah's talk starting at 7pm, after which there will be an update on the College’s latest projects and initiatives. That'll be followed by a question and answer session with senior officers and staff from the RCVS - including RCVS President Dr Niall Connell, and Chair of RCVS Veterinary Nurses (VN) Council Racheal Marshall.
Dr Connell said: "Thank you to Professor Freeman for agreeing to speak about the colic project which, through its Colic Awareness Week, is helping to raise knowledge of the early signs of colic amongst horse owners, allowing them to get their horses treated in good time and saving their lives.
"I also look forward to talking to members of the profession about some of the issues currently on their minds – the evening is very much led by what those who attend want to discuss – from mental health, to our under care review, to the Practice Standards Scheme. Attending the event can also count to up to three hours towards your continuing professional development (CPD) requirement."
The event is open to all members of the practice team including veterinary surgeons, veterinary nurses, practice managers and others. The event is free and places can be booked via the RCVS website at www.rcvs.org.uk/nottingham.
In the afternoon before the event, between 12 noon and 5pm, the College will also be holding a series of free 45-minute Practice Standards Scheme (PSS) surgeries with PSS Lead Assessor Pam Mosedale.
The surgeries are open to both RCVS-accredited practices and those considering joining the Scheme and allows delegates to discuss the assessment process, how to apply for awards, how to meet particular requirements and any other questions they may have about the PSS.
Places at the surgeries are limited and will be allocated on a first-come, first-served basis. They can be booked at: www.rcvs.org.uk/PSSsurgeries
The toolkit has been developed in conjunction with the RSPCA and includes a welfare workflow, quick download guides and welfare case forms. It can be downloaded here .
Merry Smith, a BEVA council member who led the project on behalf of BEVA, said: "Welfare assessments can sometimes be intimidating and it’s natural to feel vulnerable, particularly when circumstances are difficult. Our new Welfare Case Toolkit gives you access to the information and resources, even when you are on the road, to support you in dealing with a welfare case."
The interactive Welfare Workflow provides a step-by-step guide to what happens when a vet is called upon to provide an opinion on the health and welfare of the animals involved. It has been produced in a mobile-friendly format or can be printed out and kept in the car. Supporting the Workflow is a series of quick downloads, covering all aspects of the process:
Approach to the welfare case
Letter of instruction
Section 18 of the Animal Welfare Act (2006) certificate
Witness details sheet
Witness statement form
RSPCA vet exam form
Guidance notes on how to complete a vet exam welfare case form
Caroline Allen, Chief Veterinary Officer at the RSPCA said: "Vets are absolutely critical to the work of the RSPCA and while we know many vets get a lot of satisfaction from this work saving animals from cruelty and suffering, we know that this work can sometimes be daunting and the law confusing. We are delighted to have worked with BEVA on providing this guidance and hope it is the first step in us providing more support to vets doing this vital work- we literally couldn't do it without you"
The Welfare Case Toolkit is available free to BEVA members https://www.beva.org.uk/Resources-For-Vets-Practices/Clinical-Practice-Guidance/Welfare-guidance/Welfare-toolkit
This year the event delivered more than 90 hours of CPD lectures, workshops and practicals across six separate streams, over three days. Over 100 veterinary industry leaders showcased their wares in the commercial exhibition hall and there were a number of social events for delegates.
Delegates awarded the scientific programme an average score of 4.7 out of 5 stars, and 94% of delegates said they will put what they learnt into practice and use it in their day-to-day role. 94% also said Congress was good value for money.
Swissvet, a company which makes power dentistry equipment, won the Veterinary Practice Best New Exhibitor Award. CEO Dr Ruedi Steiger said: We have distributors throughout Europe, but it is the first time Swissvet has exhibited at BEVA. It has been a fantastic experience and I am thrilled to have won this award. I definitely plan to come back next year."
Next year’s BEVA Congress will be held in Birmingham from 9-12 September 2020. For further information visit www.beva.org.uk.
Photo: David Boughey
The survey is open to all veterinary surgeon members and participants will be entered into a free prize draw to win £500 of BEVA CPD vouchers.
As we all know, antibiotic resistance is increasing throughout human and veterinary medicine, and there are few new antibiotics being produced. As BEVA says, it’s therefore imperative for vets to protect the usage of antimicrobials to maintain their effectiveness for the future.
To that end, the purpose of the survey is to help fill in gaps in knowledge about how antimicrobials are being used and also the current landscape of resistant infections encountered in equine practice.
The survey has been designed by Amie Wilson and Dr Gina Pinchbeck at the University of Liverpool and Tim Mair the incoming President of BEVA.
Tim said: "This survey will assess any changes in prescribing of antimicrobials in equine practice since the last survey in 2009. In addition, we will collect data on the current frequency and types of antimicrobial resistant infections seen by clinicians in all areas of equine practice and what infection control and audit practices are currently using to combat this."
The survey results should lead to a greater understanding of the role of antimicrobial treatment in the overall epidemiology of antimicrobial resistance in horses and will help protect antibiotics for the future of equine and human health.
To take part in the survey, visit: https://liverpool.onlinesurveys.ac.uk/beva-questionnaire-2019-final
The results will be announced to coincide with European Antibiotic Awareness Day on 18 November 2019.
If you have any questions about the survey you can contact the researchers direct: Amie Wilson, University of Liverpool A.wilson3@liv.ac.uk; Dr Gina Pinchbeck, University of Liverpool ginap@liv.ac.uk; Tim Mair, British Equine Veterinary Association tim.mair@btinternet.com
Tim took over the role from Renate Weller at the end of BEVA Congress last week. Lucy Grieve, of Rossdales Veterinary Surgeons became President Elect.
After leaving Bristol in 1989, Tim worked in mixed practice before joining Bell Equine in 1993, becoming a partner in 1995. He led the hospital services at Bell Equine, as well as supervising the practice’s residency, intern and extern programmes, until it was bought by CVS in 2016. He continues to work as a clinician at Bell Equine whilst also working as the Equine Veterinary Director of CVS.
Tim is an RCVS Specialist in both equine internal medicine and equine soft tissue surgery and is a founding diplomate of the European College of Equine Internal Medicine; he became an Associate of the European College of Veterinary Diagnostic Imaging in 2011. He is an honorary Professor of the Royal Veterinary College and became a Fellow of the RCVS in 2016.
Editor of Equine Veterinary Education, the official journal of the British Equine Veterinary Association and the American Association of Equine Practitioners for the past 23 years, Tim has particular interests in clinical research, clinical standards and evidence based medicine, and has published widely in the professional veterinary literature, as well as authoring and editing several textbooks. He has been a member of the RCVS Practice Standards Group since 2012.
Tim has been chair of BEVA’s Education Committee since 2014, and says that during his presidential year he is keen to continue to develop BEVA’s educational activities for members at all stages of their careers.
In particular, he says he is particularly looking forward to supporting recent graduates in equine practice with relevant CPD and mentoring. He also hopes to advance the use of evidence-based veterinary medicine, and promote quality improvement in equine practice.
Tim said: "Equine practice is continuing to change and evolve with some rapidity. An important part of my focus will be on our Equine Veterinary Horizons Project, looking at anticipated advances over the next 10-15 years, what they will mean to individual practitioners and to practices and how we can adapt to and accommodate them to best advantage."
For further information visit www.beva.org.uk.
Nerfasin vet is available in two concentrations - a 100 mg/ml (10%) solution for cattle and horses and 20 mg/ml (2%) solution for cattle, horses, cats and dogs.
Nerfasin vet is on sale in 25 ml vials.
For more information visit: www.dechra.co.uk.
The review, announced earlier this year, was recommended to RCVS Council by its Standards Committee following its exploration of the implications of new technologies for both animal health and welfare and veterinary regulation.
The main areas under consideration include the provision of 24-hour emergency cover and the interpretation and application of an animal being under the care of a veterinary surgeon.
The initial stages of this review had been drafted for Standards Committee to consider at its meeting on 9 September, where the outline timetable was also discussed.
Standards Committee Chair Melissa Donald, said: "This is set to become one of our most fundamental reviews of RCVS guidance in recent years.
"Considering the complexity of the issues in question, and their importance to animal owners and the professions alike, it is vital that we allow ourselves enough time to ensure this review is as thorough and comprehensive as possible.
"We have a clear responsibility to seek, understand and, where we can, accommodate the opinions and experiences of as many different people from within and around the professions and the public as possible. I would urge my fellow vets and vet nurses to please find some time to consider these issues very carefully over the coming weeks and months, and to send us their views."
The review will comprise several stages and is expected to take around 12 months to complete. The outline timetable, which may be subject to change, is as follows:
October 2019 – January 2020: six-week Call for Evidence, followed by independent qualitative analysis of all evidence received
February – March: Select Committee-style meetings and independent qualitative analysis of additional evidence gathered [NB this stage is subject to Standards Committee requirements, depending on the evidence gathered.]
April – June: Consider all evidence and draft any new policy
July – August: six-week public consultation on draft policy
September – October: independent review of consultation responses, and production of any proposals for change
November 2020: Finalise any proposals for change and publish any new guidance
To support and promote the various stages of the review the College is also planning a programme of stakeholder engagement, and will also provide regular updates on progress to both Council and the wider profession.
Members of the professions and the public will be able to follow the progress of the review via the RCVS website at: www.rcvs.org.uk/undercare
As part of the programme, BEVA is giving the coaches workshops, discussion forums and online toolkits to develop their mentoring skills. Having been trained by a specialist mentoring professional, the coaches are then paired with recent graduates to give them guidance and support during the foundation years of their careers.
The project, called 'Leg Up', has been driven by BEVA President Renate Weller, and is being trialled over the next 12 months before being rolled out more widely.
Renate said: "All professionals, but especially new graduates need support in navigating their journey through their chosen career.
"With the veterinary industry’s rapidly changing landscape and rising concern around wellbeing, consistent support and guidance have never been more relevant."
Coaching is open to BEVA concessionary members who have graduated within the past three years. They will be able to self-select a preferred coach on a first come, first served basis from the Leg Up section of the BEVA website.
Renated added: "To date access to targeted careers support has most often depended on where you work and who you know. We hope the scheme will encourage and support those entering the profession, giving them the opportunity to discuss their training, development, career progression and self-care with trained professionals who were once in their shoes."
To find out more and to sign up for the Leg Up programme visit https://www.beva.org.uk/Careers/Leg-Up
Dexafast is an injectable corticosteroid with potent, medium-acting, anti-inflammatory activity, indicated for the treatment of a range of inflammatory and allergic conditions in both small and large animal clinical practice.
Dr John Henderson, Large Animal Product Manager at Forte Healthcare Ltd said: "Dexafast 2mg/ml is an excellent addition to our range. This formulation of dexamethasone is used across many species on a daily basis, and Dexafast 2mg/ml gives vets a high-quality presentation of a staple medicine."
Dexafast is available in a 50ml bottle.
For further information, contact your local Forte Territory Manager, visit: https://www.fortehealthcare.ie/product/dexafast-uk-only, or email: enquiries@fortehealthcare.com.
The small animal and business meeting takes place on the 2nd and 3rd October. The farm and business national meeting is on the 18th and 19th September, and the equine and business meeting is on the 9th and 10th October.
The small animal meeting will also cover other topics such as the art of conversations to dentistry, while the farm meeting will focus on team working, competitive advantage, genomics and mental resilience.
All three events include a team-based activity and a social evening which offers the chance to network and exchange experiences and ideas.
Susan Goodfellow, the Chief Marketing Officer at XLVets said: "It's fine to know what we do but to actually experience it as part of our community is quite different. We know that talking to members and being part of a group of individuals that come together to determine their own future is the best way for veterinary professionals to see what's possible and how we strive for excellence together."
XLVets is also encouraging anyone who is thinking about starting their own practice to attend the events; the company has a number of programmes designed to support prospective owners with things like finding funding, identifying the right financial set up, and acquiring the skills needed to lead a team effectively.
Susan says many vets have a strong entrepreneurial mindset but lack support or know-how to allow them to take the first step to ownership: "Locum roles and mobile set ups are often stepping stones to practice ownership but the barriers can seem significant, not to mention any personal reservations people might have about all it entails. Support from like-minded colleagues who can openly share their experiences can help to make it seem possible, desirable and achievable."
Veterinary professionals wishing to attend one of the meetings should contact Colm McGinn, Chief of Implementation, in confidence, at colm.mcginn@xlvets.co.uk or call 01228 711788.
Fynadyne had been removed from sale last year after the Veterinary Medicines Directorate suspended the sale of any medicinal products containing the excipient diethanolamine (DEA), following advice to the European Medicines Agency that it could pose a risk to human health.
Finadyne 50mg/ml Solution for Injection is indicated for the alleviation of acute inflammation and pain in both cattle and pigs. It is also indicated for the alleviation of inflammation and pain associated with musculo-skeletal disorders and colic in horses.
The reformulated product has a shelf life of three years and is now available from wholesalers in 50ml and 100ml vials.
For further information, contact your MSD Animal Health account manager.
Tranquinervin, which contains 10 mg/ml acepromazine, is indicated for anaesthetic premedication, tranquilisation and sedation.
Emma Jennings, Brand Manager at Dechra said: "Tranquinervin provides tranquillisation or a mild sedation for several hours, making it a valuable tool for many day-to-day veterinary scenarios.
"At low doses, acepromazine reduces anxiety which is beneficial for use in horses prior to shoeing or transportation. At higher dose rates, it is an effective sedative for use in situations like dentistry or handling. The relaxant effects also aid examination of the penis in horses and the treatment of tetanus and choke.
"There is also reduced anaesthetic risk reported following sole premedication with acepromazine in healthy horses1."
Tranquinervin is available in a 20 ml vial with a 56 day broached shelf life. It can be used in conjunction with Dechra’s equine anaesthesia and analgesia app which is designed to help you choose optimal anaesthetic protocols and calculate anaesthetic drug doses and administration rates quickly and easily.
For more information, go to: www.dechra.co.uk/products/equine
Reference
A test by the Australian Racing Forensic Laboratory (ARFL) of samples from a newly prepared batch of Bova’s 100mg/ml injectable omeprazole formulation did not detect testosterone, and Racing New South Wales has now released a statement that the product can continue to be used in racehorses following the guidance of Australian Commonwealth and State legislation.
Nick Bova, managing director of Bova UK, said: "Traces of testosterone in the previous batch were less than one millionth of the internationally accepted standard for impurities.
"Independent experts confirmed that there could be no adverse effects on equine health or equestrian sport, however, we have taken steps to identify and completely eliminate the excipient ingredient that contained traces of testosterone."
Nick added: "Bova can confirm that new batches of this product will not contain the previous trace levels of testosterone and therefore Bova are confident there will be no antidoping issues, no matter what the equestrian pursuit is."
The Disciplinary Committee heard three charges against Dr Jones.
The first and second charges were that, in March 2018, Dr Jones made signed entries in the passports and made corresponding entries in clinical records of four horses indicating that he had administered an influenza vaccination booster to each horse on 15 March 2018 and in relation to another horse a tetanus booster, when in fact he had administered the vaccination boosters on 21 March 2018, and that his conduct was misleading, dishonest and undermined the integrity of a vaccination process designed to promote animal welfare.
The third charge was that, on or around 21 March 2018, Dr Jones failed to make any entries in the clinical records for a horse in relation to an examination on 21 March 2018.
At the outset of the hearing Dr Jones admitted the facts in the first and second charges, and accepted that his actions were misleading, dishonest and that they undermined the integrity of a vaccination process. However, he disputed certain aspects of the written statements of the College’s witnesses. In particular he wanted his conduct to be taken in the context of the pressures that he was working under on that day, primarily that he was in a stressed state having had to euthanase a valuable stallion at the conclusion of his previous client appointment.
Dr Jones did not admit the third charge, explaining that he did not remember examining the horse on 21 March 2018 as alleged.
Based on Dr Jones' own admissions, the Committee found the first and second charges proven.
Regarding the third charge, the Committee heard evidence from the horse’s owner who said they were present during the examination taking place and the Committee was satisfied that the respondent did examine the horse on 21 March 2018 and that he had a duty to make a brief clinical note on the examination. As Dr Jones admitted that he made no such note, the Committee found the charge to have been proven to the requisite standard.
Having found the charges proven, the Committee then went on to consider whether or not Dr Jones’ proven conduct amounted to serious professional misconduct. The Committee, having considered the aggravating and mitigating factors, found that Dr Jones’ conduct as found proved in relation to both charges one and two, did constitute serious professional misconduct.
However, with regards to charge three, the Committee accepted that the respondent simply forgot that he had examined the horse and, therefore, the Committee was not satisfied that the failure to compile a record entry covering the horse’s examination constituted serious professional misconduct.
The Committee then considered what sanction to impose on Dr Jones in relation to the facts found proven in charges one and two. In doing so it took into account the 78 written testimonials and 4 character witnesses called on behalf of Dr Jones.
Ian Green, who chaired the Committee and spoke on its behalf, said: "The Committee’s decision on sanction has been based on an acceptance that the respondent’s conduct on this occasion was out-of-character, as the evidence of his character witnesses and the contents of the letters submitted in his support by his clients and other veterinary colleagues assert. The Committee also accepts that the respondent self-reported himself to his employer and to the College and has made a full and frank admission of his wrongdoing.
"Consideration was given to whether the sanction of a reprimand and/or warning as to future conduct would adequately reflect the gravity of the misconduct, however, after careful reflection it was concluded that such a sanction could not be justified. The reason is that acts of falsification involve acts of dishonesty by a professional person acting in a professional capacity, and the gravity of the matter arises not simply from the dishonesty but also from the possible consequences of the false certification. It should be clearly understood by members of the veterinary profession that, in appropriate false certification cases, the sanction of removal from the Register is one which may well be imposed."
The Committee therefore decided that suspending Dr Jones from the Register for two months would be the most appropriate sanction.
The divestment is expected to be concluded in mid-2020, and Bayer intends to exit its stake in Elanco over time.
Bayer says that combining Elanco and Bayer Animal Health will create the number two animal heath company, with top three positions across a broad range of species and geographies. It also enhances Elanco’s portfolio of leading global brands and bolsters its innovation capabilities and R&D pipeline.
Jeffrey N. Simmons, president and chief executive officer of Elanco, said: "Combining Elanco’s strong relationship with veterinarians and Bayer’s leadership in retail and e-commerce will ultimately benefit all our customers. We look forward to joining our complementary portfolios and capabilities to build a fully focused animal health company, providing a sustained flow of innovation for farmers, veterinarians and pet owners."
After the contamination was first identified, sales of the product in Australia were stopped immediately and Bova initiated an investigation.
The British Horseracing Authority then conducted its own analysis of samples of the UK product, discovering that it too was contaminated with testosterone.
However, Bova says the levels of testosterone in the end product were confirmed to be 400-700 pg/ml, which is less than one millionth of the internationally accepted standard for impurities (1 picogram being equal to one billionth of a milligram).
Nick Bova, managing Director of Bova UK, said: "We have consulted veterinary pharmacologists and sports medicine specialists who have given their opinion that these levels are within accepted standards and could neither have a clinical effect nor result in a positive blood or urine test for testosterone in competition horses.
"The levels of testosterone within the product are inconsequential compared to endogenous production in mares and geldings as well as stallions and higher levels are found frequently in feed and water sources; testosterone being a common compound produced by humans and animals from multiple organs."
The source of the contamination was traced to the excipient used in the product, which was used by Bova Aus and Bova UK. Both companies have now switched their supplier of this excipient. Bova says all testing done on the new supplier has shown no traces of testosterone, even with the new extra sensitive method of analysis which is capable of reaching picogram levels.
Nick added: "Whilst we hope to reassure you that the use of long acting injectable omeprazole will not have had adverse implications for your patients or clients we can also reassure you that we are not complacent about the presence of impurities in any of our products, particularly an impurity that is of such significance to equestrian sport.
"Although the level of impurities is well within the accepted international standard, we have changed the supplier of the excipient in question. We have established an analytical method capable of testing down to picogram levels, which has been used to test the end product to ensure there are no further concerns with future batches.
"We sincerely apologise for any inconvenience this issue may have caused. Many vets and horse owners now rely on long acting injectable omeprazole for horses that do not respond to oral treatment and we can reassure anyone who has used the product in recent months, or has product that they are due to use, that they can do so safely.
"However, we would draw attention to the recent statement from the BHA that they do not wish the product to be used in horses in training currently."
Visit www.bova.co.uk for further information.
Ophtocycline is licensed for the treatment of keratitis, conjunctivitis and blepharitis caused by Staphylococcus spp., Streptococcus spp., Proteus spp., and/or Pseudomonas spp.
Dechra says chlortetracycline hydrochloride works against both aerobic and anaerobic Gram-negative and Gram-positive bacteria.
The recommended dosage is four times a day for five days. The 10 mg/g ophthalmic ointment has a 14-day broached shelf life. There is a one-day withdrawal period for meat and offal.
Dechra Brand Manager Carol Morgan said: "Ophtocycline provides veterinary professionals with a targeted treatment to effectively tackle the growing and reproducing bacteria that causes these eye conditions.
"Chlortetracycline is a bacteriostatic antibiotic which interferes with bacterial protein synthesis in the rapidly growing and reproducing bacterial cell and has both time-dependent and concentration dependent effects.
"We are very pleased to be able to roll out this product to the UK market as part of our ophthalmic range alongside popular products such as Isathal."
For more information visit: www.dechra.co.uk
The company says the new test overcomes a major shortcoming in faecal egg counts: that they can only detect the presence of egg-laying adult worms. The new test, by contrast, can detect all stages of the small redworm life cycle, including the important encysted larval phase.
ADB says the new test will help protect the effectiveness of moxidectin, the only dewormer which is capable of eliminating the encysted stages and against which widespread resistance is not thought to have developed.
Whereas before, routine winter treatment was needed to target the encysted phase, this new test means the drug can be kept for when it is really needed, which will help prevent the development of resistance. ADB says it will also be of great value to equine vets in making differential diagnoses.
The blood test was developed by Prof Jacqui Matthews’ group at the Moredun Research Institute (MRI), with funding from The Horse Trust. She said: "It is great to see the commercialisation of this much-needed test to support sustainable worm control in horses. The test fills an important gap in our diagnostic toolbox and will enable horse owners to work with their veterinarians in targeting anthelmintic treatments against cyathostomin infections and hence help protect these important medicines for the future."
Dr Corrine Austin from ADB said: "ADB is now developing laboratory ELISA kits to enable independent veterinary laboratories to conduct blood testing; these kits are expected to reach market during 2020. Research into the saliva-based test is ongoing and is expected to be commercialised several years from now."
Veterinary practices can contact ADB at info@austindavis.co.uk to register interest in the diagnostic test service.
Amy Scott MRCVS, Boehringer Ingehlheim’s performance horse portfolio manager, said: "Arti-Cell Forte is the first 'ready-to-use' stem cell-based product to be licensed in any veterinary species, and the only stem cell treatment to contain induced cells, representing a significant leap forward in both stem cell therapies and medicine as a whole.
"Arti-Cell Forte contains stem cells that have been chondrogenically induced and therefore primed to develop into the cartilage cell lineage. Studies have shown that chondrogenically induced stem cells demonstrate an enhanced clinical outcome compared to un-induced stem cells in the treatment of joint disease in horses¹."
"This makes Arti-Cell Forte a highly targeted and effective treatment for cartilage damage associated with degenerative joint disease."
Arti-Cell Forte is available direct from Boehringer Ingelheim to veterinary practitioners.
It needs to be stored at ultra-low temperatures to maintain its two year shelf life from manufacture, either frozen at -70 ⁰C to -90 ⁰C (dry ice, -80 ⁰C freezer) or -196 ⁰C (liquid nitrogen) until immediately prior to injecting.
The company is providing full training on storage and administration via face-to-face CPD at practice meetings or specific CPD events*.
For more information, contact your local territory manager or ring Boehringer's Technical Services Team on 01344 746957, or email vetenquiries@boehringer-ingelheim.com
To win, OVs are asked to submit a question to a speaker of their choice by Monday 12 August.
The question judged the most interesting will win the free ticket and five runners up will each receive a 50% discounted ticket. In each case, the OV can choose their preferred day to attend.
The full programme can be found at: https://officialvet.com/programme/ and questions can be submitted to enquiries@improve-ov.com or by private message through Facebook at https://www.facebook.com/officialvet/
Improve says this year's speakers will address an increasing threat from notifiable diseases in the UK, with evidence of M. bovis infection linked to a raw pet food diet identified in cats, an outbreak of equine viral arteritis in Dorset and cases of African swine fever recently reported in western Europe. The programme includes small animal and farm animal focused lecture streams on both days, an equine stream on the first day and a series of specialist workshops on the second.
Dr Andrew Soldan (pictured right), Veterinary Director at APHA, said: "Notifiable diseases are an ongoing threat to the health and welfare of animals and our farming industries in the UK. Animal keepers and vets play a vital role in their early detection. We’re particularly concerned by the risk of African swine fever following the disease being found in wild boar in Belgium last year.
"Small animal and mixed practice OVs can help us reduce the risk of ASF infecting UK pigs by informing pig keepers of the risk and advising them of the importance of not feeding kitchen scraps and catering waste to pigs.
"We’re currently in the vector season so bluetongue is another disease to look out for in cattle and sheep. Providing advice to livestock farmers on how they can minimise the risk of its introduction through vaccination and checking the source of imported animals is another important role for OVs."
David Babington MRCVS, Business Development Director at Improve International, said: "OVs play a crucial role in monitoring our exposure to notifiable diseases and in alerting us to possible outbreaks. For this reason, providing a full update on the current disease status is an important element of this year’s programme, though we will also cover other important topics, including illegal puppy imports, pet travel and, inevitably I’m afraid, Brexit."
For more information on the Official Veterinarian Conference and exhibition or to register visit: www.officialvet.com.
The study, titled ‘Physics of animal health: On the mechanobiology of hoof growth and form’, represents the fruit of a collaboration between researchers in equine medicine, maths, physics and stem cell biology. It was conducted by the School of Veterinary Medicine and Science at University of Nottingham in collaboration with the Waltham Centre for Pet Nutrition and the Royal Veterinary College.
Lead author Dr Cyril Rauch said: "With new scientific inputs from physics, mathematics and biology, this study provides an entirely new paradigm regarding hard growing tissues such as the horse hoof, which can be applied across cattle, sheep and other species, to unify a set of apparently disparate conditions and clarify the roles of physics and/or biology."
Using hooves from horses euthanased for non-research purposes, the study revealed how it is possible for the hoof growth rate to be greater than the potential proliferation rate of epithelial cells. It also explained how the synthesis of the hoof capsule starts from the coronet and that the soft papillae undergo gradual transition through three interpapillary regions into hard keratinised tissue.
Mathematics, physics and cell biology were then used in the study to explain and describe how the dorsal hoof wall can grow in a curved manner rather than the usual straight manner as a result of faster growth from the coronary band at the quarters compared to the toe region.
Evaluation of the feet from live underweight and obese subjects (assessed using Body Condition Scoring) allowed the influence of body weight on the balances of the stresses affecting hoof growth to be evaluated. The results suggest that being proportionally heavier may promote straighter hoof growth and that being too lean may precipitate poor hoof growth and the development of a hoof with a dorsal curved shape.
The study also showed that a high concentration of insulin stimulated equine progenitor keratinocytes (the outermost layer of cells on the hoof wall) to grow in culture. If this also happens chronically within the live animal, it is possible that it could affect the growth stresses within the hoof and so promote a dorsal curved hoof shape.
Co-author Nicola Menzies-Gow said: "These results taken together can explain how the hoof grows and how it is possible for it to develop a dorsal curvature. However, it should be acknowledged that this does not take into account the genetic or metabolic influences on hoof growth nor the role of hoof trimming and shoeing in maintaining a mechanically healthy hoof. It is appreciated that the underlying biology of hoof growth remains an essential factor for hoof pathologies."
Dr Cyril Rauch continued: “Given that the hoof is a weight bearing element it is essential to untangle the biology from the physics in this system; only then can meaningful biological and/or physical causes be prescribed for particular hoof shape. Removing the cause(s) when physically or biologically possible is essential to resolve hoof conditions."
The equine events will initially take place at Rossdales Equine Hospital in Suffolk on 22nd October and at Ashbrook Veterinary Hospital in Cheshire on 5th December.
The roadshow will see a range of speakers renowned in the fields of equine veterinary medicine and QI share practical examples of improving outcomes for equine patients. Interactive workshops, real-life scenarios and case studies will show how QI techniques can be applied in practice to help teams prevent and respond to errors.
Confirmed speakers include Professor Debra Archer, Head of Equine Surgery and Professor in Equine Surgery at the University of Liverpool, Dr Alice Bird, Senior Clinical Anaesthetist at the Animal Health Trust and Dr Rachel Dean, Director of Clinical Research and Excellence in Practice, VetPartners.
President Elect of BEVA, Tim Mair, said: "There are many challenges to being an equine vet and running a successful equine practice. Even in large practices and equine hospitals, there is a risk that we operate in our own little bubble and assume that what we are doing is best practice, whereas in reality we could often do a better job.
"Clinical governance and quality improvement are tools that allow us to critically appraise our day-to-day work and identify ways in which we can continuously improve what we do – to the benefit of our patients and clients, as well as to ourselves."
The canine hip dysplasia roadshow will begin on 9th October in Gatwick, Surrey.
The event will review the condition prevalent in dogs, how best to investigate it and the available treatment options. Case examples will be used to show how the evidence can be evaluated, explain how to measure treatment outcomes and show how the use of checklists can help minimise potential errors.
It will be hosted by Mark Morton, RCVS Specialist in Small Animal Surgery (Orthopaedics). He said: "As vets we probably all undertake bits of QI on a day-to-day basis (whether we realise it or not!) but there is so much more we can do to embed it into our clinical work. Checklists, treatment guidelines and clinical auditing significantly improve our patient care and our outcomes.
"Whilst looking at hip dysplasia and the treatment options in detail, hopefully this roadshow will show how we can apply these ideas to improve our management of this condition as well as using them elsewhere.”
For the full programme of each event and to buy tickets, visit bit.ly/RCVSKnowledgeEvents.
Anyone interested in booking an RCVS Knowledge roadshow for their region can do so by contacting ebvm@rcvsknowledge.org.
This, says the government, would be one of the toughest sanctions in Europe, strengthening the country's claim to be a global leader on animal welfare.
The Animal Welfare (Sentencing) Bill comes after a public consultation held last year which found that more than 70% of people supported proposals for tougher prison sentences. It will allow the courts to take a tougher stance on things like dog fighting, puppy and kitten abuse, and neglect of farm animals.
The new Bill has been welcomed by animal welfare charities.
Chief Executive for the RSPCA, Chris Sherwood, said: "This reform is long overdue. Those responsible for extreme cruelty towards animals or those criminal gangs involved in organised animal crime will now face the tough justice they deserve.
"We need to better protect our animals and the RSPCA hopes that this new Animal Welfare (Sentencing) Bill will give courts the powers they need to punish those responsible for the most unimaginable cruelty to animals.
"We also believe this will act as a much stronger deterrent to others and help us stamp out animal cruelty once and for all."
James Yeates, Cats Protection’s Chief Executive said: "We very much welcome this announcement which is an important step in ensuring the UK is one of the world leaders on animal welfare issues.
Claire Horton, Chief Executive of Battersea Dogs & Cats Home, said: "The introduction of this bill is a landmark achievement, which will make a profound difference to dogs and cats in England and Wales."
Founded by Peter Rossdale in Newmarket in 1959, the practice now boasts a team of 50 veterinary surgeons and has established an international reputation for providing world class ambulatory, referral and laboratory services. The team is led by RCVS, European and American recognised veterinary specialists and operates from four sites in Newmarket, Exning, Hertfordshire and Lambourn.
Each year, Rossdales Equine Hospital in Exning hosts a large number of CPD courses which often include internationally recognised guest speakers who lecture alongside Rossdales’ specialist clinicians, with delegates attending from as far afield as Europe, Singapore, Dubai and Australia.
To celebrate the practice’s Diamond anniversary, Rossdales is hosting a special 'Diamond Series' of CPD events in 2019 in addition to its usual programme of educational courses.
Mike Shepherd, Managing Partner at Rossdales, said: "Since the practice was established by Peter Rossdale in 1959, it has always prided itself on clinical research and the willing distribution of this and other information to the veterinary profession. This ‘Diamond Anniversary’ series of CPD events is an initiative that we hope will benefit many of our veterinary colleagues. The first of these special events, the Diamond Series Veterinary Nursing Congress, was held at the beginning of June and was fully subscribed. We’re very pleased by the excellent feedback it generated."
Two further ‘Diamond Series’ events are scheduled, for veterinary surgeons and veterinary students respectively:
The Diamond Series Veterinary Surgeons Congress takes place on Friday,12th and Saturday, 13th July 2019 and is for all veterinary surgeons with an interest in equine or mixed practice. The programme covers a wide area of subjects, with talks provided by 12 veterinary surgeons from Rossdales Equine Hospital and Rossdales Laboratories. It also includes admission to The Moët & Chandon July Festival at Newmarket Racecourse on Saturday, 13th July.
The Diamond Series Undergraduate Congress will take place on Saturday, 10th and Sunday, 11th August 2019. This course is aimed at all current veterinary undergraduates who want to gain more knowledge and experience in the fields of equine veterinary medicine and surgery. There will be talks and presentations from 9 veterinary surgeons from Rossdales Equine Practice, Rossdales Equine Hospital and Rossdales Laboratories. There will also be a course dinner on the Saturday evening.
For more information, visit www.rossdales.com/news-events.